Specifically, 5-FU-SLN4 was more effective at reducing HER2 expression compared to 5-FU as shown by relatively low immunoreactivity to HER2 in 5FU-SLN4 treated tumor tissues (Fig. 6e,f). This evidence concerns the gene ERBB2 and neoplasm.